Augmenting the therapeutic window of radiotherapy: A perspective on molecularly targeted therapies and nanomaterials
Proud to present PDX Pharma’s new review article in collaboration with OHSU and University of Texas MD Anderson Cancer Center. “Augmenting the therapeutic window of radiotherapy: A perspective on molecularly targeted therapies and nanomaterials” published in Radiotherapy and Oncology.
Highlights
Targeted therapies may augment the therapeutic window of radiotherapy, but toxicities from combining radiation and targeted therapy remain a concern in certain clinical contexts.
Nanomedicines providing radiation dose enhancement or tumor-targeted therapeutic delivery are being actively explored in combination with radiation.
For clinical decision-making, discussion between radiation oncologists and medical oncologists is highly encouraged to determine the potential benefits and risks of combining targeted therapies and radiation.